Pretreatment of BAPTA-AM suppresses the genesis of repetitive endocardial focal discharges and pacing-induced ventricular arrhythmia during global ischemia

J Cardiovasc Electrophysiol. 2011 Oct;22(10):1154-62. doi: 10.1111/j.1540-8167.2011.02067.x. Epub 2011 Apr 13.

Abstract

Introduction: In isolated rabbit hearts, repetitive endocardial focal discharges (REFDs) were consistently observed during ventricular fibrillation (VF) with prolonged (>5 minutes) global ischemia (GI). We hypothesized that BAPTA-AM, a calcium chelator, can suppress these REFDs.

Methods and results: Using a two-camera optical mapping system, we simultaneously mapped endocardial (left ventricle, LV) and epicardial (both ventricles) activations during ventricular arrhythmia with GI. In 5 hearts (protocol I), we infused Tyrode's solution (no BAPTA-AM) for ≥30 minutes before the onset of no-flow GI. In 7 additional hearts (protocol II), BAPTA-AM (20 μmol/L) was infused for ≥30 minutes before the initiation of GI. In protocol I, sustained VF (>30 seconds) was successfully induced in all 5 hearts with prolonged GI. REFDs were present in >85 % of recording time. In protocol II, however, ventricular arrhythmia was not inducible and REFDs were not observed after 5-minute GI in 5 hearts. Effects of BAPTA-AM on intracellular calcium (Ca(i) ) at the LV endocardium were also evaluated in 5 hearts (protocol III) using dual Ca(i) /membrane potential mapping. GI, both without and with BAPTA-AM pretreatment, caused a decrease of Ca(i) amplitude during S(1) pacing. However, this effect was more pronounced in the hearts with BAPTA-AM pretreatment (P < 0.001). GI, without BAPTA-AM pretreatment, caused broadening of Ca(i) transient. In contrast, GI, with BAPTA-AM pretreatment, caused narrowing of Ca(i) transient.

Conclusions: BAPTA-AM pretreatment attenuates Ca(i) transient, suppressing the genesis of REFDs and pacing-induced ventricular arrhythmia during GI. These findings support the notion that Ca(i) dynamics is important in the maintenance of REFDs.

MeSH terms

  • Action Potentials
  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Calcium Signaling / drug effects*
  • Cardiac Pacing, Artificial
  • Chelating Agents / pharmacology*
  • Disease Models, Animal
  • Egtazic Acid / analogs & derivatives*
  • Egtazic Acid / pharmacology
  • Electrocardiography
  • Endocardium / drug effects*
  • Endocardium / metabolism
  • Endocardium / physiopathology
  • Fourier Analysis
  • Myocardial Ischemia / complications*
  • Myocardial Ischemia / metabolism
  • Myocardial Ischemia / physiopathology
  • Perfusion
  • Rabbits
  • Time Factors
  • Ventricular Fibrillation / etiology
  • Ventricular Fibrillation / metabolism
  • Ventricular Fibrillation / physiopathology
  • Ventricular Fibrillation / prevention & control*
  • Voltage-Sensitive Dye Imaging

Substances

  • Anti-Arrhythmia Agents
  • Chelating Agents
  • 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
  • Egtazic Acid